Starting on:
Sep 2, 2024
Ending on:
Sep 3, 2024
Moderator(s):
Go to activity
Max Credits:
2 Points
Provider:
International Cancer Institute
Claim Points
Sep 2, 2024
Ending on:
Sep 3, 2024
Moderator(s):
Prof.
Fredrick Asirwa
Prof. Fredrick Chite Asirwa M.D. is the CEO of International Cancer Institute, a not for-profit organization whose main purpose is to expand Education, Clinical Care and Training opportunities in cancer control and research across sub-Saharan Africa (SSA) through multi-sectoral collaborations and partnerships with relevant organizations both governmental and NGOs. Dr. Asirwa is a Medical Oncologist & Hematologist, PD/PI of several access to personalized cancer care and research initiatives including Blueprint Program (Kenya, Rwanda, Tanzania, Burundi, and Uganda), Shining Tower Program, Clinical Trials Program-all geared towards enhancing early detection, promoting primary HPV screening, providing SOC diagnostics & therapeutics cancer research. He has developed several training programs including SSA Oncology Preceptorship training, Digital Pathology Program, Telemedicine Program, Oncology training for Physician assistants (Clinical Officers), development of Oncology Nursing training program in Kenya, Medical Oncology Fellowship Program, Oncology Pharmacy program and assisted in the development of gynecologic oncology program. He has assisted in establishing 17 screening and early detection centers for breast and cervical cancers in Kenya working closely with the counties MOH and other local partners named EMPOWER clinics. Dr. Asirwa is also the PI of over 15 global multi-center Oncology and Hematology Clinical Trials in SSA. He was previously (2011-2019), the Director of Academic Model Providing Access to Health Care (AMPATH Oncology & Hematology Consortium) in Kenya- a consortium of a dozen Universities in the United States in partnership with Moi University and Moi Hospital in Eldoret, Kenya. In this role he conceptualized and developed infrastructure for telemedicine at AMPATH, created a robust hematology & oncology outreach program in rural Kenya and participated in the development of the Kenya National Cancer Control policies, strategic plans and guidelines by the National MOH. As PI to various clinical and research programs he established Multiple Myeloma program, Lymphoma Program, functional tumor registry, Integrated Breast & Cervical Cancer screening & treatment program, Hemophilia and Sickle cell diagnostics, treatment & research, EMR for Oncology care and screening, a multinational Lung Cancer Control Program, MLCCP (Kenya, South Africa, Lesotho, Tanzania, and Eswatini). He also teaches at various Universities in SSA and participates in Scientific Review Committees (SRC) and Data and Safety Monitoring Board (DSMB) of various Oncology/Hematology Clinical Trials both in the U.S. and SSA. He has also been an active ASCO member through ASCO’s Multidisciplinary Cancer Management Course (MCMC), International Affairs Committee (IAC), Education Council, ASCO‘s Academic Global Oncology Task Force, and as a Peer reviewer to ASCO Journals. He is also currently a member of ASCO-ESMO Global Oncology Curriculum committee, the International Association for the Study of Lung Cancer (IASLC) patient advocate committee, and one of the ASCO’s board of directors (2022-2026). He has been recognized for his work to increase access to cancer control for the underserved through various awards including the United States' National Cancer Institute's Pearline Global Cancer Research Humanitarian Award, 2020; The Children’s Place International 's 2018 Hero Award for his pioneering work in treating children and adults with cancers in Kenya. He was also awarded the 2023 Distinguished Leadership in Global Health Award by the Consortium Universities for Global Health (CUHG). He is the founder and current President of the College of Oncology of East, Central and Southern Africa (ECSA-CO) and a senate member for ECSA Health Community. He is also a distinguished Faculty speaker in both local, regional and International professional conferences and events including ASCO, ESMO, AORTIC, KESHO, Africa Cancer ECHO, APCA, UNGA, International Medical Educators Leadership Forum (IMELF), Aga Khan University’s Clinical Investigators Training Program (CITP) amongst others. He did his Undergraduate training (Bachelor of Medicine and Bachelor of Surgery) in Kenya and Post-graduate/specialty & sub-specialty training (Internal Medicine Residency & Heme/Onc Fellowship) in the United States
URL: Prof. Fredrick Chite Asirwa M.D. is the CEO of International Cancer Institute, a not for-profit organization whose main purpose is to expand Education, Clinical Care and Training opportunities in cancer control and research across sub-Saharan Africa (SSA) through multi-sectoral collaborations and partnerships with relevant organizations both governmental and NGOs. Dr. Asirwa is a Medical Oncologist & Hematologist, PD/PI of several access to personalized cancer care and research initiatives including Blueprint Program (Kenya, Rwanda, Tanzania, Burundi, and Uganda), Shining Tower Program, Clinical Trials Program-all geared towards enhancing early detection, promoting primary HPV screening, providing SOC diagnostics & therapeutics cancer research. He has developed several training programs including SSA Oncology Preceptorship training, Digital Pathology Program, Telemedicine Program, Oncology training for Physician assistants (Clinical Officers), development of Oncology Nursing training program in Kenya, Medical Oncology Fellowship Program, Oncology Pharmacy program and assisted in the development of gynecologic oncology program. He has assisted in establishing 17 screening and early detection centers for breast and cervical cancers in Kenya working closely with the counties MOH and other local partners named EMPOWER clinics. Dr. Asirwa is also the PI of over 15 global multi-center Oncology and Hematology Clinical Trials in SSA. He was previously (2011-2019), the Director of Academic Model Providing Access to Health Care (AMPATH Oncology & Hematology Consortium) in Kenya- a consortium of a dozen Universities in the United States in partnership with Moi University and Moi Hospital in Eldoret, Kenya. In this role he conceptualized and developed infrastructure for telemedicine at AMPATH, created a robust hematology & oncology outreach program in rural Kenya and participated in the development of the Kenya National Cancer Control policies, strategic plans and guidelines by the National MOH. As PI to various clinical and research programs he established Multiple Myeloma program, Lymphoma Program, functional tumor registry, Integrated Breast & Cervical Cancer screening & treatment program, Hemophilia and Sickle cell diagnostics, treatment & research, EMR for Oncology care and screening, a multinational Lung Cancer Control Program, MLCCP (Kenya, South Africa, Lesotho, Tanzania, and Eswatini). He also teaches at various Universities in SSA and participates in Scientific Review Committees (SRC) and Data and Safety Monitoring Board (DSMB) of various Oncology/Hematology Clinical Trials both in the U.S. and SSA. He has also been an active ASCO member through ASCO’s Multidisciplinary Cancer Management Course (MCMC), International Affairs Committee (IAC), Education Council, ASCO‘s Academic Global Oncology Task Force, and as a Peer reviewer to ASCO Journals. He is also currently a member of ASCO-ESMO Global Oncology Curriculum committee, the International Association for the Study of Lung Cancer (IASLC) patient advocate committee, and one of the ASCO’s board of directors (2022-2026). He has been recognized for his work to increase access to cancer control for the underserved through various awards including the United States' National Cancer Institute's Pearline Global Cancer Research Humanitarian Award, 2020; The Children’s Place International 's 2018 Hero Award for his pioneering work in treating children and adults with cancers in Kenya. He was also awarded the 2023 Distinguished Leadership in Global Health Award by the Consortium Universities for Global Health (CUHG). He is the founder and current President of the College of Oncology of East, Central and Southern Africa (ECSA-CO) and a senate member for ECSA Health Community. He is also a distinguished Faculty speaker in both local, regional and International professional conferences and events including ASCO, ESMO, AORTIC, KESHO, Africa Cancer ECHO, APCA, UNGA, International Medical Educators Leadership Forum (IMELF), Aga Khan University’s Clinical Investigators Training Program (CITP) amongst others. He did his Undergraduate training (Bachelor of Medicine and Bachelor of Surgery) in Kenya and Post-graduate/specialty & sub-specialty training (Internal Medicine Residency & Heme/Onc Fellowship) in the United States
Go to activity
Max Credits:
2 Points
Provider:
International Cancer Institute
Claim Points
Virtual Multidisciplinary Tumor Board: Brachytherapy in the Management of Gynaecological
Starting on:
Sep 2, 2024
Sep 2, 2024
Ending on:
Sep 3, 2024
Sep 3, 2024
Venue:
Description
International Cancer Institute invites you to attend the Virtual Multidisciplinary Tumor Board case presentation on solid cancers and hematological malignancies, followed by an expert discussion on patient Management. The multidisciplinary team will review recent advancement
Objectives
To understand the management of various solid cancers and hematological malignancies
To understand the importance of integrating palliative and survivorship care in cancer management
To understand the importance of a multidisciplinary team approach in cancer management
Presenters
-
Prof.
Fredrick Asirwa
Prof. Fredrick Chite Asirwa M.D. is the CEO of International Cancer Institute, a not for-profit organization whose main purpose is to expand Education, Clinical Care and Training opportunities in cancer control and research across sub-Saharan Africa (SSA) through multi-sectoral collaborations and partnerships with relevant organizations both governmental and NGOs. Dr. Asirwa is a Medical Oncologist & Hematologist, PD/PI of several access to personalized cancer care and research initiatives including Blueprint Program (Kenya, Rwanda, Tanzania, Burundi, and Uganda), Shining Tower Program, Clinical Trials Program-all geared towards enhancing early detection, promoting primary HPV screening, providing SOC diagnostics & therapeutics cancer research. He has developed several training programs including SSA Oncology Preceptorship training, Digital Pathology Program, Telemedicine Program, Oncology training for Physician assistants (Clinical Officers), development of Oncology Nursing training program in Kenya, Medical Oncology Fellowship Program, Oncology Pharmacy program and assisted in the development of gynecologic oncology program. He has assisted in establishing 17 screening and early detection centers for breast and cervical cancers in Kenya working closely with the counties MOH and other local partners named EMPOWER clinics. Dr. Asirwa is also the PI of over 15 global multi-center Oncology and Hematology Clinical Trials in SSA. He was previously (2011-2019), the Director of Academic Model Providing Access to Health Care (AMPATH Oncology & Hematology Consortium) in Kenya- a consortium of a dozen Universities in the United States in partnership with Moi University and Moi Hospital in Eldoret, Kenya. In this role he conceptualized and developed infrastructure for telemedicine at AMPATH, created a robust hematology & oncology outreach program in rural Kenya and participated in the development of the Kenya National Cancer Control policies, strategic plans and guidelines by the National MOH. As PI to various clinical and research programs he established Multiple Myeloma program, Lymphoma Program, functional tumor registry, Integrated Breast & Cervical Cancer screening & treatment program, Hemophilia and Sickle cell diagnostics, treatment & research, EMR for Oncology care and screening, a multinational Lung Cancer Control Program, MLCCP (Kenya, South Africa, Lesotho, Tanzania, and Eswatini). He also teaches at various Universities in SSA and participates in Scientific Review Committees (SRC) and Data and Safety Monitoring Board (DSMB) of various Oncology/Hematology Clinical Trials both in the U.S. and SSA. He has also been an active ASCO member through ASCO’s Multidisciplinary Cancer Management Course (MCMC), International Affairs Committee (IAC), Education Council, ASCO‘s Academic Global Oncology Task Force, and as a Peer reviewer to ASCO Journals. He is also currently a member of ASCO-ESMO Global Oncology Curriculum committee, the International Association for the Study of Lung Cancer (IASLC) patient advocate committee, and one of the ASCO’s board of directors (2022-2026). He has been recognized for his work to increase access to cancer control for the underserved through various awards including the United States' National Cancer Institute's Pearline Global Cancer Research Humanitarian Award, 2020; The Children’s Place International 's 2018 Hero Award for his pioneering work in treating children and adults with cancers in Kenya. He was also awarded the 2023 Distinguished Leadership in Global Health Award by the Consortium Universities for Global Health (CUHG). He is the founder and current President of the College of Oncology of East, Central and Southern Africa (ECSA-CO) and a senate member for ECSA Health Community. He is also a distinguished Faculty speaker in both local, regional and International professional conferences and events including ASCO, ESMO, AORTIC, KESHO, Africa Cancer ECHO, APCA, UNGA, International Medical Educators Leadership Forum (IMELF), Aga Khan University’s Clinical Investigators Training Program (CITP) amongst others. He did his Undergraduate training (Bachelor of Medicine and Bachelor of Surgery) in Kenya and Post-graduate/specialty & sub-specialty training (Internal Medicine Residency & Heme/Onc Fellowship) in the United States
International Cancer Institute